Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.50 |
| ▸ | HNF4A | P41235 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL951002 | 0.83 | ALDH1A1 (0.50) | APPHNF4ANPC1MAPTALDH1A1 | |
| SCHEMBL1931987 | 0.82 | APP (0.48) | APPHNF4ANPC1MAPTALDH1A1 | |
| SCHEMBL17010967 | 0.76 | APP (0.57) | APPHNF4ANPC1MAPTALDH1A1 | |
| SCHEMBL673209 | 0.76 | FFAR1 (0.59) | APPHNF4ANPC1MAPTALDH1A1 | |
| SCHEMBL28739815 | 0.75 | HNF4A (0.55) | APPHNF4ANPC1MAPTALDH1A1 | |
| SCHEMBL716896 | 0.73 | HNF4A (0.49) | APPHNF4ANPC1MAPTALDH1A1 | |
| SCHEMBL16720065 | 0.72 | MAPT (0.47) | APPNPC1MAPTALDH1A1MEN1 | |
| SCHEMBL30435949 | 0.72 | ALDH1A1 (0.47) | APPHNF4ANPC1MAPTALDH1A1 | |
| SCHEMBL31554912 | 0.72 | CYP1A2 (0.44) | APPHNF4ANPC1MAPTALDH1A1 | |
| SCHEMBL2114742 | 0.71 | APP (0.75) | APPNPC1MAPTALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3280402-B1 | TOLAN COMPOUNDS FOR PROMOTING WOUND HEALING | BIOMENDICS LLC (US) | 2024-06-05 | — | — | EP | disclosed |
| US-11786481-B2 | Formulation and process for modulating wound healing | BioMendics, LLC (US) | 2023-10-17 | — | — | US | disclosed |
| US-20220296538-A1 | Substituted Tolans for the Modulation of Microbial Colonization | BioMendics, LLC (US) | 2022-09-22 | — | — | US | disclosed |
| US-11351126-B2 | Substituted tolans for the modulation of microbial colonization | BioMendics, LLC (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210228501-A1 | Formulation and Process for Modulating Wound Healing | BioMendics, LLC (US) | 2021-07-29 | — | — | US | disclosed |
| US-20200206154-A1 | Substituted Tolans for the Modulation of Microbial Colonization | BioMendics, LLC (US) | 2020-07-02 | — | — | US | disclosed |
| US-10426742-B2 | Formulation and process for modulating wound healing | BioMendics, LLC (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190022029-A1 | Formulation and Process for Modulating Wound Healing | BioMendics, LLC (US) | 2019-01-24 | — | — | US | disclosed |
| US-20160296477-A1 | Formulation and Process for Modulating Wound Healing | BioMendics, LLC (US) | 2016-10-13 | — | — | US | disclosed |
| US-8716355-B2 | Hydroxylated tolans and related compounds in the treatment of a cancer | KENT STATE UNIVERSITY (US) | 2014-05-06 | — | — | US | disclosed |
| US-20110130468-A1 | HYDROXYLATED TOLANS AND RELATED COMPOUNDS IN THE TREATMENT OF A CANCER | KENT STATE UNIVERSITY (US) | 2011-06-02 | — | — | US | disclosed |
| WO-2008157787-A2 | HYDROXYLATED TOLANS AND RELATED COMPOUNDS IN THE TREATMENT OF CANCER | KENT STATE UNIVERSITY (US) | 2008-12-24 | — | — | WO | disclosed |
| US-7094809-B2 | Topical administration of dihydroxytoluene to block viral replication | NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINE (US) | 2006-08-22 | — | — | US | disclosed |
| US-20030203974-A1 | Methods for treating subjects infected with herpes virus or Neisseria gonorrheae | DOCHERTY JOHN (US) | 2003-10-30 | — | — | US | disclosed |
| US-6599945-B2 | Administering a hydroxylated tolan to the host cell of a patient having or suspected having an infection induced by herpes virus | NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINE | 2003-07-29 | — | — | US | disclosed |
| EP-1311254-A2 | METHODS FOR TREATING SUBJECTS INFECTED WITH A HERPES VIRUS OR i NEISSERIA GONORRHEAE /i | Northeastern Ohio Universities (US) | 2003-05-21 | — | — | EP | disclosed |
| US-20020103262-A1 | Methods for treating subjects infected with a herpes virus or neisseria gonorrheae | KENT STATE UNIVERSITY | 2002-08-01 | — | — | US | disclosed |
| WO-2002013764-A2 | METHODS FOR TREATING SUBJECTS INFECTED WITH A HERPES VIRUS OR NEISSERIA GONORRHEAE | NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINE (US) | 2002-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11786481-B2 | Formulation and process for modulating wound healing | SQSTM1, ATG7, TFEB | APP 4010/4885HNF4A 437/4885NPC1 4093/4885 |
| US-20200206154-A1 | Substituted Tolans for the Modulation of Microbial Colonization | LMAN1, DPM1, DSTN | APP 3466/4885HNF4A 4321/4885NPC1 3848/4885 |
| US-20160296477-A1 | Formulation and Process for Modulating Wound Healing | SQSTM1, ATG7, TFEB | APP 4260/4885HNF4A 496/4885NPC1 3952/4885 |
| US-20210228501-A1 | Formulation and Process for Modulating Wound Healing | ATG7, SQSTM1, ATF4 | APP 3850/4885HNF4A 608/4885NPC1 3956/4885 |
| US-10426742-B2 | Formulation and process for modulating wound healing | SQSTM1, ATG7, TFEB | APP 4010/4885HNF4A 437/4885NPC1 4093/4885 |
| US-20190022029-A1 | Formulation and Process for Modulating Wound Healing | SQSTM1, ATG7, TFEB | APP 4010/4885HNF4A 437/4885NPC1 4093/4885 |
| US-11351126-B2 | Substituted tolans for the modulation of microbial colonization | LMAN1, DPM1, DSTN | APP 3466/4885HNF4A 4321/4885NPC1 3848/4885 |
| US-20220296538-A1 | Substituted Tolans for the Modulation of Microbial Colonization | LMAN1, DPM1, DSTN | APP 3466/4885HNF4A 4321/4885NPC1 3848/4885 |
| US-20110130468-A1 | HYDROXYLATED TOLANS AND RELATED COMPOUNDS IN THE TREATMENT OF A CANCER | TKT, HAAO, TTPA | APP 4407/4885HNF4A 2341/4885NPC1 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.